Skip to main content

Nektar Therapeutics

NKTR
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0000906709

In the last 90 days, Nektar Therapeutics insiders filed 0 open-market purchases and 3 sales; 239 institutions reported holding it in 13F filings for Q2 2026, worth $2.50B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Nektar Therapeutics insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
3 filings
2 insiders, $441.1K in total
Insiders trading
2
Net value
−$441.1K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Nektar Therapeutics, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Nektar Therapeutics
NameTitleLast reported holdingLast filingFilings, past year
Whitfield Roy ADirector16,417Sep 25, 20262
Greer R ScottDirector22,239Sep 25, 20262
Chess RobertDirector19,019Sep 25, 20262
Brainard DianaDirector3,904Sep 25, 20262
Ajer Jeffrey RobertDirector4,277Sep 25, 20262
Zalevsky JonathanChief R&D Officer9,570Aug 20, 20269
Robin Howard WPresident & CEO54,627Aug 20, 20267
Wilson Mark AndrewChief Legal Officer21,585Nov 25, 20251
Kroin David10% Owner18,344,000IndirectMay 13, 20240
Deep Track Capital, LP10% Owner18,344,000IndirectMay 13, 20240
Deep Track Biotechnology Master Fund, Ltd.10% Owner18,344,000IndirectMay 13, 20240
Curet MyriamDirector27,418Sep 20, 20230
Thomsen Jillian B.Chief Financial Officer313,497Feb 17, 20230
Eastham KarinDirector23,233Sep 20, 20220
Labrucherie Gil MSVP, COO & CFO312,905May 17, 20220
Northcott JohnSVP & Chief Commercial Officer223,210May 17, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jul 22, 2021 (view filing)Jul 20-222 daysChess RobertDirectorSSale−5.72K$16.81−$96.1K−2.0%280.6K after3 lots
Aug 18, 2021 (view filing)Aug 16-172 daysLabrucherie Gil MSVP, COO & CFOSSale−10.9K$13.76−$149.5K−4.3%240.2K after2 lots
Aug 18, 2021 (view filing)Aug 162 daysNorthcott JohnSVP & Chief Commercial OfficerSSale−6.19K$13.83−$85.6K−3.0%200.9K after
Aug 18, 2021 (view filing)Aug 162 daysThomsen Jillian B.SVP & Chief Accounting OfficerSSale−13.3K$13.83−$184.5K−8.8%137.8K after
Aug 18, 2021 (view filing)Aug 162 daysRobin Howard WPresident & CEOSSale−11.5K$13.83−$159.3K−2.6%424.1K after
Aug 18, 2021 (view filing)Aug 162 daysWilson Mark AndrewSVP & General CounselSSale−1.91K$13.83−$26.4K−2.6%72.9K after
Aug 18, 2021 (view filing)Aug 162 daysZalevsky JonathanChief R&D OfficerSSale−7.66K$13.83−$106.0K−3.5%212.8K after
Sep 10, 2021 (view filing)Sep 8-92 daysChess RobertDirectorSSale−18.3K$16.01−$292.7K−6.2%274.3K after2 lots
Sep 24, 2021 (view filing)Sep 222 daysAjer Jeffrey RobertDirectorSSale−3.67K$17.78−$65.2K−10.1%32.5K after
Sep 24, 2021 (view filing)Sep 222 daysChess RobertDirectorSSale−4.60K$17.94−$82.5K−1.6%279.9K after
Sep 24, 2021 (view filing)Sep 222 daysCuret MyriamDirectorSSale−3.67K$17.78−$65.2K−12.4%25.8K after
Nov 17, 2021 (view filing)Nov 161 dayNorthcott JohnSVP & Chief Commercial OfficerSSale−6.06K$13.16−$79.8K−3.0%194.9K after
Nov 17, 2021 (view filing)Nov 161 dayRobin Howard WPresident & CEOSSale−42.8K$13.16−$562.9K−8.3%475.4K after
Nov 17, 2021 (view filing)Nov 161 dayThomsen Jillian B.SVP & Chief Accounting OfficerSSale−6.74K$13.16−$88.7K−4.4%146.0K after
Nov 17, 2021 (view filing)Nov 161 dayWilson Mark AndrewSVP & General CounselSSale−6.56K$13.16−$86.4K−7.1%86.4K after
Nov 17, 2021 (view filing)Nov 161 dayZalevsky JonathanChief R&D OfficerSSale−20.9K$13.16−$274.6K−8.3%232.1K after
Nov 18, 2021 (view filing)Nov 16-182 daysLabrucherie Gil MSVP, COO & CFOSSale−24.1K$13.10−$316.4K−8.6%256.7K after2 lots
Feb 18, 2022 (view filing)Feb 162 daysLabrucherie Gil MSVP, COO & CFOSSale−7.58K$10.95−$83.0K−2.5%301.6K after
Feb 18, 2022 (view filing)Feb 162 daysNorthcott JohnSVP & Chief Commercial OfficerSSale−4.85K$10.95−$53.1K−2.1%227.8K after
Feb 18, 2022 (view filing)Feb 162 daysRobin Howard WPresident & CEOSSale−12.5K$10.95−$136.7K−2.1%589.0K after
Feb 18, 2022 (view filing)Feb 162 daysThomsen Jillian B.SVP & Chief Accounting OfficerSSale−2.36K$10.95−$25.9K−1.4%165.3K after
Feb 18, 2022 (view filing)Feb 162 daysWilson Mark AndrewSVP & General CounselSSale−3.66K$10.95−$40.1K−2.9%121.1K after
Feb 18, 2022 (view filing)Feb 162 daysZalevsky JonathanChief R&D OfficerSSale−10.9K$10.95−$119.5K−3.8%274.1K after
May 17, 2022 (view filing)May 161 dayLabrucherie Gil MSVP, COO & CFOSSale−17.4K$3.95−$68.9K−5.3%312.9K after
May 17, 2022 (view filing)May 161 dayNorthcott JohnSVP & Chief Commercial OfficerSSale−4.59K$3.95−$18.1K−2.0%223.2K after
May 17, 2022 (view filing)May 161 dayRobin Howard WPresident & CEOSSale−36.5K$3.95−$144.3K−5.6%620.9K after
May 17, 2022 (view filing)May 161 dayThomsen Jillian B.SVP & Chief Accounting OfficerSSale−5.84K$3.95−$23.1K−3.3%170.4K after
May 17, 2022 (view filing)May 161 dayWilson Mark AndrewSVP & General CounselSSale−3.14K$3.95−$12.4K−2.6%117.9K after
May 17, 2022 (view filing)May 161 dayZalevsky JonathanChief R&D OfficerSSale−21.7K$3.95−$85.6K−7.3%276.4K after
Aug 17, 2022 (view filing)Aug 161 dayRobin Howard WPresident & CEOSSale−13.8K$4.76−$65.5K−1.3%1.02M after
Aug 17, 2022 (view filing)Aug 161 dayThomsen Jillian B.SVP & Chief Accounting OfficerSSale−2.01K$4.76−$9.55K−0.6%334.9K after
Aug 17, 2022 (view filing)Aug 161 dayWilson Mark AndrewSVP & General CounselSSale−3.19K$4.76−$15.2K−1.1%281.2K after
Aug 17, 2022 (view filing)Aug 161 dayZalevsky JonathanChief R&D OfficerSSale−10.6K$4.76−$50.3K−2.6%400.8K after
Aug 19, 2022 (view filing)Aug 181 dayZalevsky JonathanChief R&D OfficerSSale−73.7K$4.65−$342.8K−18.4%327.1K after
Sep 14, 2022 (view filing)Sep 131 dayEastham KarinDirectorSSale−21.3K$3.61−$76.8K−62.0%13.0K after
Sep 26, 2022 (view filing)Sep 224 daysChess RobertDirectorSSale−5.10K$3.19−$16.3K−2.2%228.2K after
Sep 26, 2022 (view filing)Sep 233 daysAjer Jeffrey RobertDirectorSSale−4.20K$3.16−$13.3K−9.8%38.5K after
Sep 26, 2022 (view filing)Sep 233 daysCuret MyriamDirectorSSale−4.20K$3.16−$13.3K−11.7%31.8K after
Nov 18, 2022 (view filing)Nov 162 daysRobin Howard WPresident & CEOSSale−38.0K$3.57−$135.7K−3.7%979.8K after
Nov 18, 2022 (view filing)Nov 162 daysThomsen Jillian B.Chief Financial OfficerSSale−11.1K$3.57−$39.6K−3.3%323.8K after
Nov 18, 2022 (view filing)Nov 162 daysWilson Mark AndrewChief Legal OfficerSSale−8.69K$3.57−$31.0K−3.1%272.5K after
Nov 18, 2022 (view filing)Nov 162 daysZalevsky JonathanChief R&D OfficerSSale−13.5K$3.57−$48.1K−4.1%313.7K after
Feb 17, 2023 (view filing)Feb 161 dayRobin Howard WPresident & CEOSSale−19.6K$3.00−$58.9K−2.0%960.2K after
Feb 17, 2023 (view filing)Feb 161 dayThomsen Jillian B.Chief Financial OfficerSSale−10.3K$3.00−$30.8K−3.2%313.5K after
Feb 17, 2023 (view filing)Feb 161 dayWilson Mark AndrewChief Legal OfficerSSale−8.28K$3.00−$24.8K−3.0%265.2K after
Feb 17, 2023 (view filing)Feb 161 dayZalevsky JonathanChief R&D OfficerSSale−10.5K$3.00−$31.5K−3.3%303.2K after
May 17, 2023 (view filing)May 161 dayRobin Howard WPresident & CEOSSale−20.4K$0.72−$14.7K−2.1%939.8K after
May 17, 2023 (view filing)May 161 dayWilson Mark AndrewChief Legal OfficerSSale−7.54K$0.72−$5.43K−2.8%257.7K after
May 17, 2023 (view filing)May 161 dayZalevsky JonathanChief R&D OfficerSSale−9.79K$0.72−$7.05K−3.2%293.4K after
Jun 15, 2023 (view filing)Jun 141 dayWhitfield Roy ADirectorSSale−30.0K$0.57−$17.1K−12.2%216.3K after10b5-1